Antibody Arrays in Biomarker Discovery

Advances in Clinical Chemistry

Volumn 69, Issue , 2015, Pages 255-324

  Wilson, Jarad J ^a   Burgess, Rob ^a   Mao, Ying Qing ^a   Luo, Shuhong ^a   Tang, Hao ^a   Jones, Valerie Sloane ^a   Weisheng, Bao ^a   Huang, Ren Yu ^a   Chen, Xuesong ^a   Huang, Ruo Pan ^a,b  

^a RayBiotech   (China)

^b South China Biochip Research Center   (China)

Author keywords

Antibody arrays; Antibody microarrays; Biomarker; Cytokine; Cytokine array; Drug target discovery; Immunoassay; Multiplexed ELISA; Protein arrays

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CYTOKINE; PROTEIN;

ASTHMA; AUTOIMMUNE DISEASE; BLOOD; DEGENERATIVE DISEASE; DRUG DEVELOPMENT; EARLY DIAGNOSIS; HUMAN; IMMUNOLOGY; KIDNEY DISEASE; PROCEDURES; PROTEIN MICROARRAY;

ANTIBODIES; ASTHMA; AUTOIMMUNE DISEASES; BIOMARKERS; CYTOKINES; DRUG DISCOVERY; EARLY DIAGNOSIS; HUMANS; KIDNEY DISEASES; NEURODEGENERATIVE DISEASES; PROTEIN ARRAY ANALYSIS; PROTEINS;

EID: 84945437751     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2015.01.002     Document Type: Chapter

References (196)

1. Soifer H.S., Rossi J.J., Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol. Ther. 2007, 15:2070-2079.
2. Rottiers V., Naar A.M. MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell Biol. 2012, 13:239-250.
3. Jiang X., Zhang D., Shi J., Chen Y., Zhang P., Mei B. Increased inflammatory response both in brain and in periphery in presenilin 1 and presenilin 2 conditional double knock-out mice. J. Alzheimers Dis. 2009, 18:515-523.
4. Coca S.G., Yalavarthy R., Concato J., Parikh C.R. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008, 73:1008-1016.
5. Ruiz-Cabello J., Cohen J.S. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 1992, 5:226-233.
6. Hattingen E., Bahr O., Rieger J., Blasel S., Steinbach J., Pilatus U. Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy. PLoS One 2013, 8:e56439.
7. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24:971-983.
8. Clyne B., Olshaker J.S. The C-reactive protein. J. Emerg. Med. 1999, 17:1019-1025.
9. Gong C.X., Liu F., Grundke-Iqbal I., Iqbal K. Post-translational modifications of tau protein in Alzheimer's disease. J. Neural Transm. 2005, 112:813-838.
10. Yang D.H., Ho L.J., Lai J.H. Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World J. Gastroenterol. 2014, 20:2962-2970.
11. Schwanhausser B., Busse D., Li N., Dittmar G., Schuchhardt J., Wolf J., Chen W., Selbach M. Global quantification of mammalian gene expression control. Nature 2011, 473:337-342.
12. Chen G., Gharib T.G., Huang C.C., Taylor J.M., Misek D.E., Kardia S.L., Giordano T.J., Iannettoni M.D., Orringer M.B., Hanash S.M., Beer D.G. Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell. Proteomics 2002, 1:304-313.
13. Hsu H.Y., Wittemann S., Joos T.O. Miniaturized parallelized sandwich immunoassays. Methods Mol. Biol. 2008, 428:247-261.
14. Kusnezow W., Banzon V., Schroder C., Schaal R., Hoheisel J.D., Ruffer S., Luft P., Duschl A., Syagailo Y.V. Antibody microarray-based profiling of complex specimens: systematic evaluation of labeling strategies. Proteomics 2007, 7:1786-1799.
15. Ray S., Chandra H., Srivastava S. Nanotechniques in proteomics: current status, promises and challenges. Biosens. Bioelectron. 2010, 25:2389-2401.
16. Luo X., Davis J.J. Electrical biosensors and the label free detection of protein disease biomarkers. Chem. Soc. Rev. 2013, 42:5944-5962.
17. Huang R.P. Detection of multiple proteins in an antibody-based protein microarray system. J. Immunol. Methods 2001, 255:1-13.
18. Pei R., Cheng Z., Wang E., Yang X. Amplification of antigen-antibody interactions based on biotin labeled protein-streptavidin network complex using impedance spectroscopy. Biosens. Bioelectron. 2001, 16:355-361.
19. Ladd J., Taylor A.D., Piliarik M., Homola J., Jiang S. Label-free detection of cancer biomarker candidates using surface plasmon resonance imaging. Anal. Bioanal. Chem. 2009, 393:1157-1163.
20. Schweitzer B., Roberts S., Grimwade B., Shao W., Wang M., Fu Q., Shu Q., Laroche I., Zhou Z., Tchernev V.T., Christiansen J., Velleca M., Kingsmore S.F. Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat. Biotechnol. 2002, 20:359-365.
21. Woodbury R.L., Varnum S.M., Zangar R.C. Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. J. Proteome Res. 2002, 1:233-237.
22. Spisak S., Tulassay Z., Molnar B., Guttman A. Protein microchips in biomedicine and biomarker discovery. Electrophoresis 2007, 28:4261-4273.
23. Wingren C., Borrebaeck C.A. Antibody-based microarrays. Methods Mol. Biol. 2009, 509:57-84.
24. Chandra H., Reddy P.J., Srivastava S. Protein microarrays and novel detection platforms. Expert Rev. Proteomics 2011, 8:61-79.
25. Kingsmore S.F. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat. Rev. Drug Discov. 2006, 5:310-320.
26. Borrebaeck C.A., Wingren C. High-throughput proteomics using antibody microarrays: an update. Expert Rev. Mol. Diagn. 2007, 7:673-686.
27. Baraldi-Junkins C.A., Beck A.C., Rothstein G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol. Oncol. Clin. North Am. 2000, 14:45-61. viii.
28. Gerard C., Rollins B.J. Chemokines and disease. Nat. Immunol. 2001, 2:108-115.
29. Zagury D., Le B.H., Bizzini B., Burny A., Lewis G., Gallo R.C. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev. 2003, 14:123-137.
30. Barnes P.J. Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev. 2003, 14:511-522.
31. Andreakos E. Targeting cytokines in autoimmunity: new approaches, new promise. Expert Opin. Biol. Ther. 2003, 3:435-447.
32. de Wildt R.M., Mundy C.R., Gorick B.D., Tomlinson I.M. Antibody arrays for high-throughput screening of antibody-antigen interactions. Nat. Biotechnol. 2000, 18:989-994.
33. Torres C., Perales S., Alejandre M.J., Iglesias J., Palomino R.J., Martin M., Caba O., Prados J.C., Aranega A., Delgado J.R., Irigoyen A., Ortuno F.M., Rojas I., Linares A. Serum cytokine profile in patients with pancreatic cancer. Pancreas 2014, 43:1042-1049.
34. Nomura S., Yoshitomi H., Takano S., Shida T., Kobayashi S., Ohtsuka M., Kimura F., Shimizu H., Yoshidome H., Kato A., Miyazaki M. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br. J. Cancer 2008, 99:305-313.
35. Chen X., Li J., Hu W., Yang S., Gong Y. Differential gene expression of human keratinocyte HaCaT cells induced by fibroblast growth factor 10 treatment. Mol. Cell. Biochem. 2010, 342:71-85.
36. Mroczko B., Szmitkowski M., Wereszczynska-Siemiatkowska U., Jurkowska G. Hematopoietic cytokines in the sera of patients with pancreatic cancer. Clin. Chem. Lab. Med. 2005, 43:146-150.
37. Mroczko B., Szmitkowski M., Wereszczynska-Siemiatkowska U., Jurkowska G. Stem cell factor and macrophage-colony stimulating factor in patients with pancreatic cancer. Clin. Chem. Lab. Med. 2004, 42:256-260.
38. Horstmann M., Hennenlotter J., Geiger L.M., Vogel U., Schmid H., Kuehs U., Stenzl A., Bedke J. Evaluation of the KIT/stem cell factor axis in renal tumours. Anticancer Res 2012, 32:4339-4345.
39. Gest C., Joimel U., Huang L., Pritchard L.L., Petit A., Dulong C., Buquet C., Hu C.Q., Mirshahi P., Laurent M., Fauvel-Lafeve F., Cazin L., Vannier J.P., Lu H., Soria J., Li H., Varin R., Soria C. Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines. BMC Cancer 2013, 13:63.
40. Li Y., Flores R., Yu A., Okcu M.F., Murray J., Chintagumpala M., Hicks J., Lau C.C., Man T.K. Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer 2011, 117:207-217.
41. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
42. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
43. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
44. Gragoudas E.S., Adamis A.P., Cunningham E.T., Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004, 351:2805-2816.
45. Lucio-Eterovic A.K., Piao Y., de Groot J.F. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 2009, 15:4589-4599.
46. Lin Y., Huang R., Chen L., Li S., Shi Q., Jordan C., Huang R.P. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int. J. Cancer 2004, 109:507-515.
47. Chen T., Lu Y.H., Wang W.J., Bian C.Y., Cheng X.Y., Su Y., Zhou P.M. Elevated urinary levels of cystatin C and neutrophil gelatinase-associated lipocalin in Henoch-Schonlein purpura patients with renal involvement. PLoS One 2014, 9:e101026.
48. Sachdeva N., Asthana D. Cytokine quantitation: technologies and applications. Front. Biosci. 2007, 12:4682-4695.
49. Wu J.Q., Wang B., Belov L., Chrisp J., Learmont J., Dyer W.B., Zaunders J., Cunningham A.L., Dwyer D.E., Saksena N.K. Antibody microarray analysis of cell surface antigens on CD4+ and CD8+ T cells from HIV+ individuals correlates with disease stages. Retrovirology 2007, 4:83.
50. + elite controller: a proteomic analysis of cytokines 2012.
51. Callaway E. Clues emerge to explain first successful HIV vaccine trial. Nature 2011, 1038:541.
52. Gold P., Freedman S.O. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 1965, 121:439-462.
53. Bergstrand C.G., Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand. J. Clin. Lab. Invest. 1956, 8:174.
54. Abelev G.I., Perova S.D., Khramkova N.I., Postnikova Z.A., Irlin I.S. Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation 1963, 1:174-180.
55. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12:278-287.
56. Hsueh C.T., Liu D., Wang H. Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomark. Res. 2013, 1:1.
57. De S., Razorenova O., McCabe N.P., O'Toole T., Qin J., Byzova T.V. VEGF-integrin interplay controls tumor growth and vascularization. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:7589-7594.
58. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
59. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
60. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A.B., Shi Q., McLendon R.E., Bigner D.D., Rich J.N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006, 66:7843-7848.
61. Abajo A., Bitarte N., Zarate R., Boni V., Lopez I., Gonzalez-Huarriz M., Rodriguez J., Bandres E., Garcia-Foncillas J. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World J. Gastroenterol. 2012, 18:637-645.
62. Li C., Simeone D.M., Brenner D.E., Anderson M.A., Shedden K.A., Ruffin M.T., Lubman D.M. Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J. Proteome Res. 2009, 8:483-492.
63. Chen Y.C., Wang P.W., Pan T.L., Bazylak G., Shen J.J. Proteomic analysis of plasma to reveal the impact of short-term etanercept therapy in pediatric patients with enthesitis-related arthritis: a case report. Comb. Chem. High Throughput Screen. 2010, 13:469-481.
64. Woo J.H., Lee H.J., Sung I.H., Kim T.H. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J. Rheumatol. 2007, 34:1753-1759.
65. Dhir V., Sandhu A., Gupta N., Dhawan V., Sharma S., Sharma A. Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritis. ISRN Inflamm. 2013, 2013:460469.
66. Navarro-Sobrino M., Rosell A., Hernandez-Guillamon M., Penalba A., Boada C., Domingues-Montanari S., Ribo M., Alvarez-Sabin J., Montaner J. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis 2011, 216:205-211.
67. Wadsworth S., Sin D., Dorscheid D. Clinical update on the use of biomarkers of airway inflammation in the management of asthma. J. Asthma Allergy 2011, 4:77-86.
68. Patil S.P., Wisnivesky J.P., Busse P.J., Halm E.A., Li X.M. Detection of immunological biomarkers correlated with asthma control and quality of life measurements in sera from chronic asthmatic patients. Ann. Allergy Asthma Immunol. 2011, 106:205-213.
69. Kim H.B., Kim C.K., Iijima K., Kobayashi T., Kita H. Protein microarray analysis in patients with asthma: elevation of the chemokine PARC/CCL18 in sputum. Chest 2009, 135:295-302.
70. Matsunaga K., Yanagisawa S., Ichikawa T., Ueshima K., Akamatsu K., Hirano T., Nakanishi M., Yamagata T., Minakata Y., Ichinose M. Airway cytokine expression measured by means of protein array in exhaled breath condensate: correlation with physiologic properties in asthmatic patients. J. Allergy Clin. Immunol. 2006, 118:84-90.
71. Ichikawa T., Matsunaga K., Minakata Y., Yanagisawa S., Ueshima K., Akamatsu K., Hirano T., Nakanishi M., Sugiura H., Yamagata T., Ichinose M. Possible impact of salivary influence on cytokine analysis in exhaled breath condensate. Anal. Chem. Insights 2007, 2:85-92.
72. Nakamura K., Okumura K., Mikuniya M. Is analysis of exhaled breath condensate equivalent to that of bronchoalveolar lavage fluid?. Eur. Respir. J. 2011, 38:476.
73. Matsunaga K., Ichikawa T., Yanagisawa S., Akamatsu K., Koarai A., Hirano T., Sugiura H., Minakata Y., Ichinose M. Clinical application of exhaled breath condensate analysis in asthma: prediction of FEV1 improvement by steroid therapy. Respiration 2009, 78:393-398.
74. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 2007, 13:1359-1362.
75. Bjorkqvist M., Ohlsson M., Minthon L., Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One 2012, 7:e29868.
76. Doecke J.D., Laws S.M., Faux N.G., Wilson W., Burnham S.C., Lam C.P., Mondal A., Bedo J., Bush A.I., Brown B., De R.K., Ellis K.A., Fowler C., Gupta V.B., Head R., Macaulay S.L., Pertile K., Rowe C.C., Rembach A., Rodrigues M., Rumble R., Szoeke C., Taddei K., Taddei T., Trounson B., Ames D., Masters C.L., Martins R.N. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 2012, 69:1318-1325.
77. O'Bryant S.E., Xiao G., Barber R., Huebinger R., Wilhelmsen K., Edwards M., Graff-Radford N., Doody R., Diaz-Arrastia R. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One 2011, 6:e28092.
78. Rossignol D.A., Frye R.E. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol. Psychiatry 2012, 17:389-401.
79. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol. 2005, 57:67-81.
80. Freund A., Orjalo A.V., Desprez P.Y., Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol. Med. 2010, 16:238-246.
81. Heneka M.T., O'Banion M.K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 2007, 184:69-91.
82. Maggio M., Guralnik J.M., Longo D.L., Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J. Gerontol. A Biol. Sci. Med. Sci. 2006, 61:575-584.
83. Choi C., Jeong J.H., Jang J.S., Choi K., Lee J., Kwon J., Choi K.G., Lee J.S., Kang S.W. Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology. J. Clin. Neurol. 2008, 4:84-88.
84. Newsom D.M., Liggitt H.D., O'Rourke K., Zhuang D., Schneider D.A., Harrington R.D. Cytokine antibody array analysis in brain and periphery of scrapie-infected Tg338 mice. Comp. Immunol. Microbiol. Infect. Dis. 2011, 34:387-397.
85. Mari A., Alessandri C., Bernardi M.L., Ferrara R., Scala E., Zennaro D. Microarrayed allergen molecules for the diagnosis of allergic diseases. Curr. Allergy Asthma Rep. 2010, 10:357-364.
86. Paczesny S., Krijanovski O.I., Braun T.M., Choi S.W., Clouthier S.G., Kuick R., Misek D.E., Cooke K.R., Kitko C.L., Weyand A., Bickley D., Jones D., Whitfield J., Reddy P., Levine J.E., Hanash S.M., Ferrara J.L. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
87. Frampton J.P., White J.B., Simon A.B., Tsuei M., Paczesny S., Takayama S. Aqueous two-phase system patterning of detection antibody solutions for cross-reaction-free multiplex ELISA. Sci. Rep. 2014, 4:4878.
88. Kunz M., Ibrahim S.M. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm. 2009, 2009:979258.
89. Castro S.V., Jimenez S.A. Biomarkers in systemic sclerosis. Biomark. Med. 2010, 4:133-147.
90. Bauer J.W., Baechler E.C., Petri M., Batliwalla F.M., Crawford D., Ortmann W.A., Espe K.J., Li W., Patel D.D., Gregersen P.K., Behrens T.W. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006, 3:e491.
91. Carlsson A., Wuttge D.M., Ingvarsson J., Bengtsson A.A., Sturfelt G., Borrebaeck C.A., Wingren C. Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays. Mol. Cell. Proteomics 2011, 10:M110.
92. Petersson L., Dexlin-Mellby L., Bengtsson A.A., Sturfelt G., Borrebaeck C.A., Wingren C. Multiplexing of miniaturized planar antibody arrays for serum protein profiling-a biomarker discovery in SLE nephritis. Lab Chip 2014, 14:1931-1942.
93. Kokkonen H., Soderstrom I., Rocklov J., Hallmans G., Lejon K., Rantapaa D.S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010, 62:383-391.
94. Hueber W., Tomooka B.H., Zhao X., Kidd B.A., Drijfhout J.W., Fries J.F., van Venrooij W.J., Metzger A.L., Genovese M.C., Robinson W.H. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann. Rheum. Dis. 2007, 66:712-719.
95. Wright H.L., Bucknall R.C., Moots R.J., Edwards S.W. Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford) 2012, 51:451-459.
96. Raza K., Falciani F., Curnow S.J., Ross E.J., Lee C.Y., Akbar A.N., Lord J.M., Gordon C., Buckley C.D., Salmon M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 2005, 7:R784-R795.
97. Hughes-Austin J.M., Deane K.D., Derber L.A., Kolfenbach J.R., Zerbe G.O., Sokolove J., Lahey L.J., Weisman M.H., Buckner J.H., Mikuls T.R., O'Dell J.R., Keating R.M., Gregersen P.K., Robinson W.H., Holers V.M., Norris J.M. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: studies of the Aetiology of Rheumatoid Arthritis (SERA). Ann. Rheum. Dis. 2013, 72:901-907.
98. Burska A., Boissinot M., Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014, 2014:545493.
99. Chandra P.E., Sokolove J., Hipp B.G., Lindstrom T.M., Elder J.T., Reveille J.D., Eberl H., Klause U., Robinson W.H. Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res. Ther. 2011, 13:R102.
100. Centola M., Cavet G., Shen Y., Ramanujan S., Knowlton N., Swan K.A., Turner M., Sutton C., Smith D.R., Haney D.J., Chernoff D., Hesterberg L.K., Carulli J.P., Taylor P.C., Shadick N.A., Weinblatt M.E., Curtis J.R. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One 2013, 8:e60635.
101. Curtis J.R., van der Helm-van Mil A.H., Knevel R., Huizinga T.W., Haney D.J., Shen Y., Ramanujan S., Cavet G., Centola M., Hesterberg L.K., Chernoff D., Ford K., Shadick N.A., Hamburger M., Fleischmann R., Keystone E., Weinblatt M.E. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res. (Hoboken) 2012, 64:1794-1803.
102. Hagman S., Raunio M., Rossi M., Dastidar P., Elovaara I. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study. J. Neuroimmunol. 2011, 234:141-147.
103. Tumani H., Kassubek J., Hijazi M., Lehmensiek V., Unrath A., Sussmuth S., Lauda F., Kapfer T., Fang L., Senel M., Brettschneider J. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. Eur. Neurol. 2011, 65:164-169.
104. Oreja-Guevara C., Ramos-Cejudo J., Aroeira L.S., Chamorro B., Diez-Tejedor E. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurol. 2012, 12:95.
105. Martins T.B., Rose J.W., Jaskowski T.D., Wilson A.R., Husebye D., Seraj H.S., Hill H.R. Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am. J. Clin. Pathol. 2011, 136:696-704.
106. Comabella M., Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014, 13:113-126.
107. Katsavos S., Anagnostouli M. Biomarkers in multiple sclerosis: an up-to-date overview. Mult. Scler. Int. 2013, 2013:340508.
108. Fengming Y., Jianbing W. Biomarkers of inflammatory bowel disease. Dis. Markers 2014, 2014:710915.
109. Bennike T., Birkelund S., Stensballe A., Andersen V. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J. Gastroenterol. 2014, 20:3231-3244.
110. Kader H.A., Tchernev V.T., Satyaraj E., Lejnine S., Kotler G., Kingsmore S.F., Patel D.D. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am. J. Gastroenterol. 2005, 100:414-423.
111. Alex P., Zachos N.C., Nguyen T., Gonzales L., Chen T.E., Conklin L.S., Centola M., Li X. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 2009, 15:341-352.
112. Knutson C.G., Mangerich A., Zeng Y., Raczynski A.R., Liberman R.G., Kang P., Ye W., Prestwich E.G., Lu K., Wishnok J.S., Korzenik J.R., Wogan G.N., Fox J.G., Dedon P.C., Tannenbaum S.R. Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2332-E2341.
113. Hostmann A., Kapp K., Beutner M., Ritz J.P., Loddenkemper C., Ignatius R., Duchmann R., Daum S., Grone J., Hotz H., Buhr H.J., Zeitz M., Ullrich R. Dendritic cells from human mesenteric lymph nodes in inflammatory and non-inflammatory bowel diseases: subsets and function of plasmacytoid dendritic cells. Immunology 2013, 139:100-108.
114. Coburn L.A., Horst S.N., Chaturvedi R., Brown C.T., Allaman M.M., Scull B.P., Singh K., Piazuelo M.B., Chitnavis M.V., Hodges M.E., Rosen M.J., Williams C.S., Slaughter J.C., Beaulieu D.B., Schwartz D.A., Wilson K.T. High-throughput multi-analyte Luminex profiling implicates eotaxin-1 in ulcerative colitis. PLoS One 2013, 8:e82300.
115. Rodriguez-Peralvarez M.L., Garcia-Sanchez V., Villar-Pastor C.M., Gonzalez R., Iglesias-Flores E., Muntane J., Gomez-Camacho F. Role of serum cytokine profile in ulcerative colitis assessment. Inflamm. Bowel Dis. 2012, 18:1864-1871.
116. Ohman L., Dahlen R., Isaksson S., Sjoling A., Wick M.J., Sjovall H., Van O.L., Simren M., Strid H. Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease. Inflamm. Bowel Dis. 2013, 19:2433-2439.
117. Meeker R.B., Poulton W., Markovic-Plese S., Hall C., Robertson K. Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection. J. Neurovirol. 2011, 17:258-273.
118. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
119. Sanchez-Carbayo M. Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens. Tumour Biol. 2010, 31:103-112.
120. Kopf E., Zharhary D. Antibody arrays-an emerging tool in cancer proteomics. Int. J. Biochem. Cell Biol. 2007, 39:1305-1317.
121. Zolg J.W., Langen H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics 2004, 3:345-354.
122. Huang R., Jiang W., Yang J., Mao Y.Q., Zhang Y., Yang W., Yang D., Burkholder B., Huang R.F., Huang R.P. A biotin label-based antibody array for high-content profiling of protein expression. Cancer Genomics Proteomics 2010, 7:129-141.
123. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
124. Yeretssian G., Lecocq M., Lebon G., Hurst H.C., Sakanyan V. Competition on nitrocellulose-immobilized antibody arrays: from bacterial protein binding assay to protein profiling in breast cancer cells. Mol. Cell. Proteomics 2005, 4:605-617.
125. Kim B.K., Lee J.W., Park P.J., Shin Y.S., Lee W.Y., Lee K.A., Ye S., Hyun H., Kang K.N., Yeo D., Kim Y., Ohn S.Y., Noh D.Y., Kim C.W. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res. 2009, 11:R22.
126. Sanchez-Carbayo M., Socci N.D., Lozano J.J., Haab B.B., Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 2006, 168:93-103.
127. Lassus P., Janer J., Haglund C., Karikoski R., Andersson L.C., Andersson S. Consistent expression of HGF and c-met in the perinatal lung. Biol. Neonate 2006, 90:28-33.
128. Humphrey P.A., Zhu X., Zarnegar R., Swanson P.E., Ratliff T.L., Vollmer R.T., Day M.L. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 1995, 147:386-396.
129. Li Y., Guessous F., Johnson E.B., Eberhart C.G., Li X.N., Shu Q., Fan S., Lal B., Laterra J., Schiff D., Abounader R. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab. Invest. 2008, 88:98-111.
130. You H., Ding W., Dang H., Jiang Y., Rountree C.B. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011, 54:879-889.
131. Dieterle F., Sistare F., Goodsaid F., Papaluca M., Ozer J.S., Webb C.P., Baer W., Senagore A., Schipper M.J., Vonderscher J., Sultana S., Gerhold D.L., Phillips J.A., Maurer G., Carl K., Laurie D., Harpur E., Sonee M., Ennulat D., Holder D., Andrews-Cleavenger D., Gu Y.Z., Thompson K.L., Goering P.L., Vidal J.M., Abadie E., Maciulaitis R., Jacobson-Kram D., Defelice A.F., Hausner E.A., Blank M., Thompson A., Harlow P., Throckmorton D., Xiao S., Xu N., Taylor W., Vamvakas S., Flamion B., Lima B.S., Kasper P., Pasanen M., Prasad K., Troth S., Bounous D., Robinson-Gravatt D., Betton G., Davis M.A., Akunda J., McDuffie J.E., Suter L., Obert L., Guffroy M., Pinches M., Jayadev S., Blomme E.A., Beushausen S.A., Barlow V.G., Collins N., Waring J., Honor D., Snook S., Lee J., Rossi P., Walker E., Mattes W. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat. Biotechnol. 2010, 28:455-462.
132. Westenfelder C. Earlier diagnosis of acute kidney injury awaits effective therapy. Kidney Int. 2011, 79:1159-1161.
133. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark. Med. 2010, 4:265-280.
134. Hu H., Kwun J., Aizenstein B.D., Knechtle S.J. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 2009, 87:1814-1820.
135. Srivastava M., Eidelman O., Torosyan Y., Jozwik C., Mannon R.B., Pollard H.B. Elevated expression levels of ANXA11, integrins beta3 and alpha3, and TNF-alpha contribute to a candidate proteomic signature in urine for kidney allograft rejection. Proteomics Clin. Appl. 2011, 5:311-321.
136. Neiman M., Hedberg J.J., Donnes P.R., Schuppe-Koistinen I., Hanschke S., Schindler R., Uhlen M., Schwenk J.M., Nilsson P. Plasma profiling reveals human fibulin-1 as candidate marker for renal impairment. J. Proteome Res. 2011, 10:4925-4934.
137. Liu B.C., Zhang L., Lv L.L., Wang Y.L., Liu D.G., Zhang X.L. Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am. J. Nephrol. 2006, 26:483-490.
138. Stevenson W., Chauhan S.K., Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch. Ophthalmol. 2012, 130:90-100.
139. Lemp M., Sullivan B., Crews L. Biomarkers in dry eye disease. Eur. Opthal. Rev. 2012, 6:157.
140. Hagan S., Tomlinson A. Tear fluid biomarker profiling: a review of multiplex bead analysis. Ocul. Surf. 2013, 11:219-235.
141. Massingale M.L., Li X., Vallabhajosyula M., Chen D., Wei Y., Asbell P.A. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009, 28:1023-1027.
142. VanDerMeid K.R., Su S.P., Ward K.W., Zhang J.Z. Correlation of tear inflammatory cytokines and matrix metalloproteinases with four dry eye diagnostic tests. Invest. Ophthalmol. Vis. Sci. 2012, 53:1512-1518.
143. Lee S.Y., Han S.J., Nam S.M., Yoon S.C., Ahn J.M., Kim T.I., Kim E.K., Seo K.Y. Analysis of tear cytokines and clinical correlations in Sjogren syndrome dry eye patients and non-Sjogren syndrome dry eye patients. Am. J. Ophthalmol. 2013, 156:247-253.
144. Benito M.J., Gonzalez-Garcia M.J., Teson M., Garcia N., Fernandez I., Calonge M., Enriquez-de-Salamanca A. Intra- and inter-day variation of cytokines and chemokines in tears of healthy subjects. Exp. Eye Res. 2014, 120:43-49.
145. Wei Y., Gadaria-Rathod N., Epstein S., Asbell P. Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures. Invest. Ophthalmol. Vis. Sci. 2013, 54:8327-8336.
146. khashu H., Baiju C., Bansal S., Chhillar A. Salivary biomarkers: a periodontal overview. J. Oral Health Commun. Dent. 2012, 6:28-33.
147. Sexton W.M., Lin Y., Kryscio R.J., Dawson D.R., Ebersole J.L., Miller C.S. Salivary biomarkers of periodontal disease in response to treatment. J. Clin. Periodontol. 2011, 38:434-441.
148. Williamson S., Munro C., Pickler R., Grap M.J., Elswick R.K. Comparison of biomarkers in blood and saliva in healthy adults. Nurs. Res. Pract. 2012, 2012:246178.
149. Browne R.W., Kantarci A., LaMonte M.J., Andrews C.A., Hovey K.M., Falkner K.L., Cekici A., Stephens D., Genco R.J., Scannapieco F.A., Van Dyke T.E., Wactawski-Wende J. Performance of multiplex cytokine assays in serum and saliva among community-dwelling postmenopausal women. PLoS One 2013, 8:e59498.
150. Zia A., Khan S., Bey A., Gupta N.D., Mukhtar U.N. Oral biomarkers in the diagnosis and progression of periodontal disease in response to treatment. Biol. Med. 2011, 3:45-52.
151. Fiorini T., Vianna P., Weidlich P., Musskopf M.L., Moreira C.H., Chies J.A., Rosing C.K., Oppermann R.V., Susin C. Relationship between cytokine levels in serum and gingival crevicular fluid (GCF) in pregnant women. Cytokine 2012, 58:34-39.
152. Papathanasiou E., Teles F., Griffin T., Arguello E., Finkelman M., Hanley J., Theoharides T.C. Gingival crevicular fluid levels of interferon-gamma, but not interleukin-4 or -33 or thymic stromal lymphopoietin, are increased in inflamed sites in patients with periodontal disease. J. Periodontal Res. 2014, 49:55-61.
153. Fu Q.Y., Zhang L., Duan L., Qian S.Y., Pang H.X. Correlation of chronic periodontitis in tropical area and IFN-gamma, IL-10, IL-17 levels. Asian Pac. J. Trop. Med. 2013, 6:489-492.
154. Thunell D.H., Tymkiw K.D., Johnson G.K., Joly S., Burnell K.K., Cavanaugh J.E., Brogden K.A., Guthmiller J.M. A multiplex immunoassay demonstrates reductions in gingival crevicular fluid cytokines following initial periodontal therapy. J. Periodontal Res. 2010, 45:148-152.
155. Reis C., DA Costa A.V., Guimaraes J.T., Tuna D., Braga A.C., Pacheco J.J., Arosa F.A., Salazar F., Cardoso E.M. Clinical improvement following therapy for periodontitis: association with a decrease in IL-1 and IL-6. Exp. Ther. Med. 2014, 8:323-327.
156. Shimada Y., Tabeta K., Sugita N., Yoshie H. Profiling biomarkers in gingival crevicular fluid using multiplex bead immunoassay. Arch. Oral Biol. 2013, 58:724-730.
157. Baird G.S., Montine T.J. Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy. Arch. Pathol. Lab. Med. 2008, 132:232-238.
158. De P.B., De Bleecker J.L. Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy. Mediators Inflamm. 2013, 2013:540370.
159. De P.B., Creus K.K., Martin J.J., De Bleecker J.L. Upregulation of chemokines and their receptors in Duchenne muscular dystrophy: potential for attenuation of myofiber necrosis. Muscle Nerve 2012, 46:917-925.
160. Ayoglu B., Chaouch A., Lochmuller H., Politano L., Bertini E., Spitali P., Hiller M., Niks E.H., Gualandi F., Ponten F., Bushby K., Aartsma-Rus A., Schwartz E., Le P.Y., Straub V., Uhlen M., Cirak S., 't Hoen P.A., Muntoni F., Ferlini A., Schwenk J.M., Nilsson P., Al-Khalili S.C. Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO Mol. Med. 2014, 6:918-936.
161. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Crit. Care 2010, 14:R15.
162. Holub M., Lawrence D.A., Andersen N., Davidova A., Beran O., Maresova V., Chalupa P. Cytokines and chemokines as biomarkers of community-acquired bacterial infection. Mediators Inflamm. 2013, 2013:190145.
163. Kofoed K., Schneider U.V., Scheel T., Andersen O., Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin. Chem. 2006, 52:1284-1293.
164. Bozza F.A., Salluh J.I., Japiassu A.M., Soares M., Assis E.F., Gomes R.N., Bozza M.T., Castro-Faria-Neto H.C., Bozza P.T. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit. Care 2007, 11:R49.
165. Shapiro N.I., Trzeciak S., Hollander J.E., Birkhahn R., Otero R., Osborn T.M., Moretti E., Nguyen H.B., Gunnerson K.J., Milzman D., Gaieski D.F., Goyal M., Cairns C.B., Ngo L., Rivers E.P. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit. Care Med. 2009, 37:96-104.
166. Lvovschi V., Arnaud L., Parizot C., Freund Y., Juillien G., Ghillani-Dalbin P., Bouberima M., Larsen M., Riou B., Gorochov G., Hausfater P. Cytokine profiles in sepsis have limited relevance for stratifying patients in the emergency department: a prospective observational study. PLoS One 2011, 6:e28870.
167. Wong H.L., Pfeiffer R.M., Fears T.R., Vermeulen R., Ji S., Rabkin C.S. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol. Biomarkers Prev. 2008, 17:3450-3456.
168. de Paz J.L., Seeberger P.H. Recent advances and future challenges in glycan microarray technology. Methods Mol. Biol. 2012, 808:1-12.
169. Park S., Gildersleeve J.C., Blixt O., Shin I. Carbohydrate microarrays. Chem. Soc. Rev. 2013, 42:4310-4326.
170. Wandall H.H., Blixt O., Tarp M.A., Pedersen J.W., Bennett E.P., Mandel U., Ragupathi G., Livingston P.O., Hollingsworth M.A., Taylor-Papadimitriou J., Burchell J., Clausen H. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010, 70:1306-1313.
171. Pedersen J.W., Blixt O., Bennett E.P., Tarp M.A., Dar I., Mandel U., Poulsen S.S., Pedersen A.E., Rasmussen S., Jess P., Clausen H., Wandall H.H. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer 2011, 128:1860-1871.
172. Gao C., Liu Y., Zhang H., Zhang Y., Fukuda M.N., Palma A.S., Kozak R.P., Childs R.A., Nonaka M., Li Z., Siegel D.L., Hanfland P., Peehl D.M., Chai W., Greene M.I., Feizi T. Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array. J. Biol. Chem. 2014, 289:16462-16477.
173. Wolf-Yadlin A., Sevecka M., MacBeath G. Dissecting protein function and signaling using protein microarrays. Curr. Opin. Chem. Biol. 2009, 13:398-405.
174. Price J.V., Haddon D.J., Kemmer D., Delepine G., Mandelbaum G., Jarrell J.A., Gupta R., Balboni I., Chakravarty E.F., Sokolove J., Shum A.K., Anderson M.S., Cheng M.H., Robinson W.H., Browne S.K., Holland S.M., Baechler E.C., Utz P.J. Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J. Clin. Invest. 2013, 123:5135-5145.
175. Zhang B., Jarrell J.A., Price J.V., Tabakman S.M., Li Y., Gong M., Hong G., Feng J., Utz P.J., Dai H. An integrated peptide-antigen microarray on plasmonic gold films for sensitive human antibody profiling. PLoS One 2013, 8:e71043.
176. Anderson K.S., Sibani S., Wallstrom G., Qiu J., Mendoza E.A., Raphael J., Hainsworth E., Montor W.R., Wong J., Park J.G., Lokko N., Logvinenko T., Ramachandran N., Godwin A.K., Marks J., Engstrom P., Labaer J. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J. Proteome Res. 2011, 10:85-96.
177. Miersch S., Bian X., Wallstrom G., Sibani S., Logvinenko T., Wasserfall C.H., Schatz D., Atkinson M., Qiu J., Labaer J. Serological autoantibody profiling of type 1 diabetes by protein arrays. J. Proteomics 2013, 94:486-496.
178. Paweletz C.P., Charboneau L., Bichsel V.E., Simone N.L., Chen T., Gillespie J.W., Emmert-Buck M.R., Roth M.J., Petricoin E.F., Liotta L.A. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20:1981-1989.
179. Gujral T.S., Karp R.L., Finski A., Chan M., Schwartz P.E., MacBeath G., Sorger P. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene 2013, 32:3470-3476.
180. Simon R.J., Kania R.S., Zuckermann R.N., Huebner V.D., Jewell D.A., Banville S., Ng S., Wang L., Rosenberg S., Marlowe C.K. Peptoids: a modular approach to drug discovery. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:9367-9371.
181. Reddy M.M., Wilson R., Wilson J., Connell S., Gocke A., Hynan L., German D., Kodadek T. Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 2011, 144:132-142.
182. Heine N., Ast T., Schneider-Mergener J., Reineke U., Germeroth L., Wenschuh H. Synthesis and screening of peptoid arrays on cellulose membranes. Tetrahedron 2003, 59:9919-9930.
183. Woodward W.A., Sulman E.P. Cancer stem cells: markers or biomarkers?. Cancer Metastasis Rev. 2008, 27(3):459-470.
184. Narod S.A., Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 2004, 4(9):665-676.
185. Mah W.C., Lee C.G. DNA methylation: potential biomarker in Hepatocellular Carcinoma. Biomark. Res. 2014, 2(1):5.
186. Stuhlmuller B., et al. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 2010, 87(3):311-321.
187. Catalona W.J., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 1994, 151(5):1283-1290.
188. Gulbis B., et al. Mass concentration of creatine kinase MB isoenzyme and lactate dehydrogenase isoenzyme 1 in diagnosis of perioperative myocardial infarction after coronary bypass surgery. Clin. Chem. 1990, 36(10):1784-1788.
189. Uusimaa P., et al. Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension. Acta Cardiol. 2011, 66(1):21-27.
190. Yang D.H., Ho L.J., Lai J.H. Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World J. Gastroenterol. 2014, 20(11):2962-2970.
191. Rudolf J., Lewandrowski K.B. Cholesterol, lipoproteins, high-sensitivity c-reactive protein, and other risk factors for atherosclerosis. Clin. Lab. Med. 2014, 34(1):113-127. vii.
192. Owens M., et al. Elevated morning cortisol is a stratified population-level biomarker for major depression in boys only with high depressive symptoms. Proc. Natl. Acad. Sci. U. S. A 2014, 111(9):3638-3643.
193. Carlsen A.L., et al. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum. 2013, 65(5):1324-1334.
194. Albrecht H., Carraway K.L. MUC1 and MUC4: switching the emphasis from large to small. Cancer Biother. Radiopharm. 2011, 26(3):261-271.
195. Drake R.R., Kislinger T. The proteomics of prostate cancer exosomes. Expert. Rev. Proteomics. 2014, 11(2):167-177.
196. Zhao Y., et al. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med. 2012, 10:153.